Live attenuated influenza vaccine (FluMist®; Fluenz™): A review of its use in the prevention of seasonal influenza in children and adults

Drugs

Volumn 71, Issue 12, 2011, Pages 1591-1622

  Carter, Natalie J ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Influenza virus infections; Influenza virus vaccine; Influenza virus vaccine live

Indexed keywords

CHICKENPOX VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE;

ADULT; ASTHMA; CELLULAR IMMUNITY; CHILD; CHILL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HEADACHE; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION; INFECTION PREVENTION; INFESTATION; INFLUENZA A; INFLUENZA B; MEDIASTINUM DISEASE; MYALGIA; NOSE CONGESTION; PHASE 3 CLINICAL TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; RHINORRHEA; SEASONAL INFLUENZA; SEROCONVERSION; SINGLE DRUG DOSE; SINUSITIS; SORE THROAT; SYSTEMATIC REVIEW; THORAX DISEASE; VIRUS SHEDDING; VIRUS TRANSMISSION; WEAKNESS; WHEEZING;

ADULT; CHILD; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEASONS; VACCINES, ATTENUATED;

ORTHOMYXOVIRIDAE; TIPULA IRIDESCENT VIRUS;

EID: 80052015820     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206860-000000000-00000     Document Type: Review

References (65)

1. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363: 2036-44
2. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010 Aug 6; 59 (RR-8): 1-62
3. Beyer WEP, Palache AM, de Jong JC, et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: a meta-analysis. Vaccine 2002 Jan 31; 20 (9-10): 1340-53 (Pubitemid 34131675)
4. Tosh PK, Boyce TG, Poland GA. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc 2008 Jan; 83 (1): 77-84
5. Buonagurio DA, Bechert TM, Yang C-F, et al. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine 2006 Mar 15; 24 (12): 2151-60 (Pubitemid 43255158)
6. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Resp Virus 2008 Nov; 2 (6): 193-202
7. WHO. Recommendations for influenza vaccine composition [online]. Available from URL: http://www.who.int/csr/disease/influenza/ vaccinerecommendations1/en/index.html [Accessed 2011 Feb 9]
8. Tam JS, Capeding MRZ, Lum LCS, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007 Jul; 26 (7): 619-28 (Pubitemid 47014164)
9. Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccinetrivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006 Dec; 118 (6): 2298-312 (Pubitemid 46397567)
10. Monto AS. Seasonal influenza vaccinations: specialized products for different target groups. Vaccine 2010 Sep; 28 Suppl. 4: D14-23
11. WHO. Global pandemic influenza action plan to increase vaccine supply: progress report 2008 (WHO/IVB/09/05) [online]. Available fromURL: http://whqlibdoc.who.int/hq/2009/WHO-IVB-09.05-eng.pdf [Accessed 2011 Mar 14]
12. MedImmune LLC. FluMist intranasal live attentuated influenza vaccine, 2010-2011 formula: US prescribing information [online]. Available from URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/Approved Products/ucm123743.pdf [Accessed 2010 Sep 20]
13. MedImmune. Fluenz intranasal live attenuated influenza vaccine: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001101/WC500103709.pdf [Accessed 2011 Jun 16]
14. AstraZeneca Canada. FluMist intranasal live attentuated influenza vaccine: Canadian product monograph [online]. Available from URL: http://www.astrazeneca.ca/docu ments/ProductPortfolio/FLUMIST-PM-en.pdf [Accessed 2011 Jun 16]
15. MedImmune. FDA approves MedImmune's refrigerated formulation of FluMist [online]. Available from URL: http://pressroom.medimmune.com/press-releases/ 2007/01/08/fda-approves-medimmune-s-refrigerated-formulation-offlumist-r/ [Accessed 2011 Mar 9]
16. Block SL, Reisinger KS, Hultquist M, et al. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007 Nov; 51 (11): 4001-8 (Pubitemid 350057799)
17. Belshe RB, GruberWC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000 May; 19 (5 Suppl. 1): S66-71 (Pubitemid 30308024)
18. Bracco Neto H, Farhat CK, Tregnaghi MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009 May; 28 (5): 365-71
19. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007 Feb 15; 356 (7): 685-96
20. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006 Oct; 25 (10): 870-9 (Pubitemid 44510578)
21. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006 Oct; 25 (10): 860-9 (Pubitemid 44510577)
22. Lum LCS, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010; 28: 1566-74
23. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136 (2): 168-75 (Pubitemid 30470986)
24. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338 (20): 1405-12 (Pubitemid 28221981)
25. Yang CF, Belshe RB, Kemble G, et al. Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine 2010 Jul 12; 28 (31): 5128-34
26. Ambrose C, Levin M, Belshe R. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5 (2): 67-75
27. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008 Sep 12; 26 Suppl. 4: D10-6
28. Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010 Sep; 29 (9): 806-11
29. Belshe RB, Toback SL, Yi T, et al. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respi Viruses 2010 May 1; 4 (3): 141-5
30. Block SL, Heikkinen T, Toback SL, et al. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011 Mar; 30 (3): 203-7
31. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against cultureconfirmed influenza virus in young children. Clin Vaccine Immunol 2008 Jul; 15 (7): 1042-53 (Pubitemid 352018317)
32. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999 Jul 14; 282 (2): 137-44 (Pubitemid 29323803)
33. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009 Sep 24; 361 (13): 1260-7
34. Davis MM, King JC, Moag L, et al. Countywide schoolbased influenza immunization: direct and indirect impact on student absenteeism. Pediatrics 2008 Jul; 122 (1): e260-5
35. Glezen WP, Gaglani MJ, Kozinetz CA, et al. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis 2010 Dec 1; 202 (11): 1626-33
36. King JC, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006 Dec; 355 (24): 2523-32 (Pubitemid 44917500)
37. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A(H1N1),A(H3N2), and B viruses. Vaccine 2000; 18 (9-10): 899-906
38. Bergen R, Black S, Shinefield H, et al. Safety of coldadapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004 Feb; 23 (2): 138-44 (Pubitemid 38222786)
39. Ambrose C, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Resp Virus Epub 2011 Apr 4
40. Bernstein DI, Yan L, Treanor J, et al. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003 Jan; 22 (1): 28-34 (Pubitemid 36091774)
41. King Jr JC, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live coldadapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000; 181: 725-8 (Pubitemid 30131847)
42. Levin MJ, Song L-Y, Fenton T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008 Aug 5; 26 (33): 4210-7
43. Block SL, Yogev R, Hayden FG, et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008 Sep 8; 26 (38): 4940-6
44. Nolan T, Bernstein DI, Block SL, et al. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008 Mar; 121 (3): 508-16
45. Breiman RF, Brooks WA, Goswami D, et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 2009 Sep 4; 27 (40): 5472-9
46. Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 2000 Aug 20; 18 (1-2): 82-8
47. European Committee for Proprietary Medicinal Products. Points to consider on the development of live attenuated influenza vaccines: EMEA/CPMP/BWP/2289/01 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC5000 03899.pdf [Accessed 2011 Apr 2]
48. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, coldadapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181 (3): 1133-7 (Pubitemid 30194502)
49. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006 Jul; 25 (7): 590-5 (Pubitemid 43995354)
50. Weinberg A, Song L-Y, Walker R, et al. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acq Imm Defic Syn 2010 Oct 1; 55 (2): 189-96
51. Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005 May; 26 (5): 494-500 (Pubitemid 40695285)
52. He X-S, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006 Dec; 80 (23): 11756-66 (Pubitemid 44788888)
53. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007 Jan; 81 (1): 215-28 (Pubitemid 44975162)
54. Glasgow JFT. Reye's syndrome: the case for a causal link with aspirin. Drug Saf 2006; 29 (12): 1111-21
55. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009 Apr 15; 48: 1003-32
56. Monto AS. Seasonal influenza and vaccination coverage. Vaccine 2010 Sep; 28 Suppl. 4: D33-44
57. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009 Jul 31; 58 (RR-8): 1-52
58. Centers for Disease Control and Prevention. Interim estimates of cumulative influenza vaccination coverage for 2010-11 season: United States, end of February 2011 [online]. Available from URL: http://www.cdc.gov/flu/ professionals/vaccination/reporti1011/reportII/[Accessed 2011 Aug 11]
59. HealthyPeople. Healthy people 2020 objectives: immunization and infectious diseases [online]. Available from URL: http://www.healthypeople.gov/ 2020/topicsobjectives2020/objectiveslist.aspx?topicid=23 [Accessed 2011 Mar 8]
60. Poland GA. The 2009-2010 influenza pandemic: effects on pandemic and seasonal vaccine uptake and lessons learned for seasonal vaccination campaigns. Vaccine 2010 Sep; 28 Suppl. 4: D3-13
61. WHO. Global pandemic influenza action plan to increase vaccine supply: WHO/IVB/06.13 [online]. Available from URL: http://whqlibdoc.who.int/hq/2006/ WHO-IVB-06. 13-eng.pdf [Accessed 2011 Mar 11]
62. Centers for Disease Control and Prevention. Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 2009 Oct 9; 58 (39): 1100-1
63. MedImmune. Intranasal live influenza A (H1N1) 2009 monovalent vaccine: highlights of the US prescribing information [online]. Available from URL: http://info.pub licintelligence.net/MedImmune%20H1n1%20PI%20(2).pdf [Accessed 2011 Jul 6]
64. WHO. Meeting with international partners on influenza vaccine production technology transfer to developing countries: WHO/IVB/10.10 [online]. Available from URL: http://whqlibdoc.who.int/hq/2010/WHO-IVB-10.10-eng. pdf [Accessed 2011 Mar 14]
65. Schering-Plough. Nobilon advances intranasal seasonal influenza vaccine into proof of concept study [online]. Available from URL: http://www.merck.com/ newsroom/news-release-archive/schering-plough-news-archive/all/re leaseid=1341213.html [Accessed 2009 Oct 13]